M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Cloretazine
Drug: Fludarabine

First Posted Date: 2007-08-28

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00521859

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Erythropoietin
Drug: Cyclosporin A
Drug: G-CSF
Drug: Prednisone

First Posted Date: 2007-08-24

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00520468

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Procedure: 3-Dimensional Conformal Radiation Therapy
Procedure: Intensity Modulated Radiation Therapy

First Posted Date: 2007-08-24

Last Posted Date: 2018-10-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 168

Registration Number: NCT00520702

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients

Terminated

Conditions: Cervical Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-08-22

Last Posted Date: 2020-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT00519272

Locations: 🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States

Perceptions of Cervical Cancer Among Asian Americans

Completed

Conditions: Epidemiology

Interventions: Behavioral: Focus Group
Behavioral: Questionnaire

First Posted Date: 2007-08-20

Last Posted Date: 2016-01-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00518388

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

CHESS: Human and Computer Mentors for Prostate Cancer Patients

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: CHESS System
Behavioral: Cancer Information Mentor

First Posted Date: 2007-08-15

Last Posted Date: 2018-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 209

Registration Number: NCT00516256

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

Phase 3

Terminated

Conditions: Breast Cancer
Fatigue
Gastrointestinal Cancer

Interventions: Drug: Methylphenidate
Drug: Placebo

First Posted Date: 2007-08-15

Last Posted Date: 2018-01-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00516269

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Phase 1

Terminated

Conditions: Neoplastic Meningitis

Interventions: Drug: DepoCyt
Drug: Temozolomide

First Posted Date: 2007-08-14

Last Posted Date: 2012-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00515788

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Papillary Serous Carcinoma of the Endometrium

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Paclitaxel
Radiation: Pelvic Radiation
Drug: Dexamethasone
Drug: Cimetidine
Drug: Diphenhydramine

First Posted Date: 2007-08-13

Last Posted Date: 2014-07-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00515073

Locations: 🇺🇸
M. D. Anderson Cancer Center - Orlando, Orlando, Florida, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Depression Treatment and Screening in Ovarian Cancer Patients

Phase 1

Active, not recruiting

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions: Other: Telephone Counseling
Other: Usual Care

First Posted Date: 2007-08-13

Last Posted Date: 2024-03-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 409

Registration Number: NCT00515372

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy